The expression of microvesicles in the blood of patients with Graves' disease and its relationship to treatment

Clinical Endocrinology

Volumn 84, Issue 5, 2016, Pages 729-735

  Mobarrez, Fariborz ^a,e   Abraham Nordling, Mirna ^b   Aguilera Gatica, Katherina ^a   Friberg, Inger ^a   Antovic, Aleksandra ^a   Pisetsky, David S ^c,d   Jörneskog, Gun ^a   Wallen, Håkan ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH MOBILITY GROUP B1 PROTEIN; LEVOTHYROXINE SODIUM; PADGEM PROTEIN; THIAMAZOLE; THYROID HORMONE; THYROTROPIN; ANTITHYROID AGENT;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; INFLAMMATION; MALE; MEMBRANE MICROPARTICLE; MONOCYTE; PRIORITY JOURNAL; BLOOD; DRUG EFFECTS; EXOSOME; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; THROMBOCYTE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTITHYROID AGENTS; BLOOD PLATELETS; CD40 LIGAND; CELL-DERIVED MICROPARTICLES; E-SELECTIN; ENDOTHELIAL CELLS; EXTRACELLULAR VESICLES; FEMALE; FLOW CYTOMETRY; GRAVES DISEASE; HMGB1 PROTEIN; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED; MONOCYTES; P-SELECTIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84945297413     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12872     Document Type: Article

References (28)

1. Abraham-Nordling, M., Byström, K., Törring, O., et al,. (2011) Incidence of hyperthyroidism in Sweden. European Journal of Endocrinology, 165, 899-905.
2. Menconi, F., Marcocci, C., &, Marinò, M., (2014) Diagnosis and classification of Graves' disease. Autoimmunity Reviews, 13, 398-402.
3. Osman, F., Gammage, M.D., &, Franklyn, J.A., (2001) Thyroid disease and its treatment: short-term and long-term cardiovascular consequences. Current Opinion in Pharmacology, 1, 626-631.
4. Cooper, D.S., (2003) Hyperthyroidism. Lancet, 362, 459-468.
5. Sundaresh, V., Brito, J.P., Wang, Z., et al,. (2013) Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. Journal of Clinical Endocrinology and Metabolism, 98, 3671-3677.
6. Roos, M.A., Gennero, L., Denysenko, T., et al,. (2010) Microparticles in physiological and in pathological conditions. Cell Biochemistry and Function, 28, 539-548.
7. Burger, D., Schock, S., Thompson, C.S., et al,. (2012) Microparticles: biomarkers and beyond. Clinical Science, 124, 423-441.
8. Ullal, A.J., Pisetsky, D.S., &, Reich, C.F., (2010) Use of SYTO 13, a fluorescent dye binding nucleic acids, for the detection of microparticles in in vitro systems. Cytometry A, 77, 294-301.
9. Soop, A., Hållström, L., Frostell, C., et al,. (2013) Effect of lipopolysaccharide administration on the number, phenotype and content of nuclear molecules in blood microparticles of normal human subjects. Scandinavian Journal of Immunology, 78, 205-213.
10. Dasgupta, S.K., Guchhait, P., &, Thiagarajan, P., (2006) Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Translational Research, 148, 19-25.
11. Faulstich, H., Zobeley, S., Heintz, D., et al,. (1993) Probing the phalloidin binding site of actin. FEBS Letters, 318, 218-222.
12. Mobarrez, F., Antovic, J., Egberg, N., et al,. (2010) A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thrombosis Research, 125, e110-e116.
13. Vikerfors, A., Mobarrez, F., Bremme, K., et al,. (2012) Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus, 25, 802-805.
14. Panzer, S., Haubenstock, A., &, Minar, E., (1990) Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indium-labeled plateletkinetics, and platelet-associated immunoglobulins G and M. The Journal of Clinical Endocrinology and Metabolism, 72, 491-496.
15. Yamamoto, K., Itoh, M., Okamura, T., et al,. (2012) Relative levels of the inflammatory cytokine TNFα and the soluble CD40 ligand profile in serum correlate with the thyrotoxic activity of Graves' disease. Thyroid, 22, 516-521.
16. Mobarrez, F., Sjövik, C., Soop, A., et al,. (2014) CD40L expression in plasma of volunteers following LPS administration: a comparison between assay of CD40L on platelet microvesicles and soluble CD40L. Platelets, 25, 1-5.
17. Guidollet, J., Chignier, E., Pillot, R., et al,. (1999) Enhanced expression of P-selectin (CD62P) by endothelial cells seeded onto synthetic arterial prostheses (PET, Dacron) is correlated with leukocyte interactions. Journal of Biomedical Materials Research, 44, 156-161.
18. Kuznik, B.I., Vitkovsky, Y.A., Gvozdeva, O.V., et al,. (2014) Lymphocyte-platelet crosstalk in Graves' disease. American Journal of the Medical Sciences, 347, 206-210.
19. Li, Y., Chen, H., Tan, J., et al,. (1998) Impaired release of tissue plasminogen activator from the endothelium in Graves' disease-indicator of endothelial dysfunction and reduced fibrinolytic capacity. European Journal of Clinical Investigation, 28, 1050-1054.
20. Hara, H., Sugita, E., Sato, R., et al,. (1996) Plasma selectin levels in patients with Graves' disease. Endocrine Journal, 43, 709-713.
21. Aubert, V.D., Béné, M.C., Leclère, J., et al,. (1995) CD31, CD62E, and CD62P identify a specific pattern of endothelial activation in Graves' disease. Clinical Immunology and Immunopathology, 76, 170-179.
22. Sera, N., Kawakami, A., Nakashima, T., et al,. (2001) Fas/FasL mediated apoptosis of thyrocytes in Graves' disease. Clinical and Experimental Immunology, 124, 197-207.
23. Rouhiainen, A., Imai, S., Rauvala, H., et al,. (2000) Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thrombosis and Haemostasis, 84, 1087-1094.
24. Chen, Y., Sun, W., Gao, R., et al,. (2013) The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology, 52, 1739-1747.
25. Pisetsky, D.S., Gauley, J., &, Ullal, A.J., (2011) HMGB1 and microparticles as mediators of the immune response to cell death. Antioxidants & Redox Signaling, 15, 2209-2219.
26. Ullal, A.J., Reich, C.F. III, Clowse, M., et al,. (2011) Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. Journal of Autoimmunity, 36, 173-180.
27. Cooper, D.S., (2005) Antithyroid drugs. The New England Journal of Medicine, 352, 905-917.
28. Kim, H., Lee, T.H., Hwang, Y.S., et al,. (2001) Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging. Molecular Pharmacology, 60, 972-980.